Welcome to the PACIFICA Trial Information Portal

This is an educational resource for health care professionals to learn more about the ongoing trial and to determine the eligibility for patient enrollment in the trial

Research Overview

The PACIFICA trial is a randomized, controlled phase 3 study of pacritinib versus Physician's Choice1 in patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post‑essential thrombocythemia myelofibrosis with severe thrombocytopenia (platelet count <50,000/µL).

1Physician’s Choice is limited to single drugs from the following list: corticosteroids, hydroxyurea, danazol, or low-dose ruxolitinib.

Shape
Image
PACIFICA Trial Objectives

The primary objective of the trial is to compare the efficacy of pacritinib with that of P/C therapy, as assessed by the proportion of patients achieving a ≥35% SVR between baseline and Week 24 as measured by MRI (preferred) or CT scans.

Secondary objectives include:

  • To compare the efficacy of pacritinib with P/C therapy, as assessed by the proportion of patients achieving a ≥50% reduction in Total symptom score (TSS) between baseline and Week 24
  • To compare the overall survival of patients treated with pacritinib versus those treated with P/C
  • To compare the percentage of patients who self-assess as “very much improved” or “much improved” as measured by the Patient Global Impression of Change (PGIC) in patients treated with pacritinib versus those treated with P/C

PACIFICA Trial Site Locations

Study enrollment is open in the following countries. For full list of clinical sites, visit ClinicalTrials.gov.

World Map
  • United States
  • Israel
  • Australia
  • Italy
  • Belarus
  • Republic of Korea
  • Bulgaria
  • Poland
  • Canada
  • Russian Federation
  • Czechia
  • Serbia
  • France
  • Spain
  • Georgia
  • Ukraine
  • Hungary
  • United Kingdom



Contact Us

© Copyright 2021 CTI BioPharma Corp.

cti-biopharma